News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Hexima.
RELATED STOCKHEAD STORIES
News
Top 10 at 10: Data-tech firm Pointerra is living the US dream while Zeus digs in
Experts
After scaring everyone in 2022 it looks like ASX health stocks will have a pulse in 2023
News
These were the 40 worst performing small and large capped ASX stocks in 2022
Health & Biotech
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
Health & Biotech
Clinical Trials 101: The critical review process and getting drugs to market
Experts
THE SUNDAY ROAST: The ASX small caps that lit a fire under Stockhead’s experts this week
News
Trading Places: Who is buying in BIG and selling out of ASX stocks?
Health & Biotech
ASX Health Stocks: Lumos down 65pc on FDA rejection; and is Hexima belly-up after Phase 2 readout?
Health & Biotech
ScoPo’s Powerplays: ASX health stocks show signs of jittery recovery
News
Closing Bell: Vulcan and Leo prove there’s two sides to the lithium coin as the ASX closes the week out ahead
Experts
ScoPo’s Powerplays: Who else needs help remembering the good times of ASX health stocks?
Health & Biotech
Check up: 78 biotech companies rocked the boat this week but only one has real news
Health & Biotech
China is about to grant patents like never before, and these ASX stocks have already got some
Health & Biotech
ASX Health Stocks: AFT Pharma jumps 13pc on FDA submission, Imugene up 10pc on CAR-T progress
News
September Winners Column: A rough month but uranium and lithium managed gains. And caravan renters
Health & Biotech
Check Up: Paradigm targets Phase 3 clinical trial in the US; AI microbiology product fails to impress
Health & Biotech
